The antiphospholipid (Hughes') syndrome: Changing the face of neurology

European Journal of Internal Medicine

Volumn 15, Issue 3, 2004, Pages 147-150

  Lampropoulos, Christos E ^a   Hughes, Graham R V ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Anticoagulation therapy; Antiphospholipid antibodies; Antiphospholipid syndrome; Neurological manifestations

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; CEREBRAL SINUS THROMBOSIS; CHOREA; CLINICAL FEATURE; COGNITIVE DEFECT; CORRELATION ANALYSIS; DEMENTIA; DISEASE ASSOCIATION; DISEASE COURSE; DYSTONIA; EPILEPSY; EYE DISEASE; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL HYPERTENSION; MENTAL DISEASE; MIGRAINE; MULTIPLE SCLEROSIS; MYELITIS; NEUROLOGIC DISEASE; OCCLUSIVE CEREBROVASCULAR DISEASE; PARKINSONISM; PATHOGENESIS; PERCEPTION DEAFNESS; PLASMAPHERESIS; REVIEW; STATISTICAL SIGNIFICANCE; STROKE; TIC; TRANSIENT GLOBAL AMNESIA; VERTIGO;

EID: 3142636800     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2004.01.017     Document Type: Review

References (49)

1. Hughes G.R.V. Thrombosis, abortion, cerebral disease and the lupus anticoagulant. Br. Med. J. 287:1983;1088-1089
2. Wilson W.A., Gharavi A.E., Koike T., et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42:1999;1309-1311
3. Hughes G.R.V. The Prosser-White oration 1983. Connective tissue disease and the skin. Clin. Exp. Dermatol. 9:1984;535-544
4. Ziporen L., Shoenfeld Y., Levy Y., Korczyn A.D. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies. A mouse model. J. Clin. Invest. 100:1997;613-619
5. Kent M.N., Alvarez F.J., Ng A.K., Rote N.S. Ultrastructural localization of monoclonal antiphospholipid antibody binding to rat brain. Exp. Neurol. 163:2000;173-179
6. Caronti B., Calderaro C., Alessandri C., et al. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J. Autoimmun. 11:1998;425-429
7. Chapman J., Cohen Armon M., Shoenfeld Y., Korczyn A.D. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus. 8:1999;127-133
8. Emmi L., Bergamini C., Spinelli A., et al. Possible pathogenetic role of activated platelets in the primary antiphospholipid syndrome involving the central nervous system. Ann. New York Acad. Sci. 823:1997;188-200
9. Harris E.N., Gharavi A.E., Asherson R.A., Boey M.L., Hughes G.R.V. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies. Clin. Exp. Rheumatol. 2:1984;47-51
10. Asherson R.A., Khamashta M.A., Gil A., et al. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease and the primary antiphospholipid syndrome. Am. J. Med. 86:1989;391-399
11. Provenzale J.M., Barboriak D.P., Allen N.B., Ortel T.L. Patients with antiphospholipid antibodies: CT and MR findings of the brain. Am. J. Roentgenol. 167:1996;1573-1578
12. Devinsky O., Petito C.K., Alonso D.R. Clinical and neuropathological findings in systemic lupus erythematosus: the role of vasculitis, heart emboli and thrombotic thrombocytopenic purpura. Ann. Neurol. 23:1988;380-384
13. Khamashta M.A., Cervera R., Asherson R.A., et al. Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus. Lancet. 335:1990;1541-1544
14. Kushner M., Simonian L. Lupus anticoagulants, anticardiolipin antibodies and cerebral ischemia. Stroke. 20:1989;225-229
15. Deschiens M.A., Conard J., Horellou M.H., et al. Coagulation studies, factor V Leiden and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke. 27:1996;1724-1730
16. Asherson R., Mercey D., Phillips G., et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann. Rheum. Dis. 46:1987;605-611
17. Westerman E.M., Miles J.M., Backonja M., Sundstrom W.R. Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event. Arthritis Rheum. 35:1992;1038-1041
18. Hilker R., Thiel A., Geisen C., Rudolf J. Cerebral blood flow and glucose metabolism in multi-infarct dementia related to primary antiphospholipid antibody syndrome. Lupus. 9:2000;311-316
19. Mosek A., Yust I., Treves T.A., Vardinon N., Korczyn A.D., Chapman J. Dementia and antiphospholipid antibodies. Dementia Geriatr. Cogn. Disord. 11:2000;36-38
20. Cuadrado M.J., Khamashta M.A., Hughes G.R.V. Sticky blood and headache. Lupus. 10:2001;392-393
21. Hughes G.R.V. Migraine, memory loss and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome. Postgrad. Med. J. 79:2003;81-83
22. Hughes G.R.V., Cuadrado M.J., Khamashta M.A., Sanna G. Headache and memory loss: rapid response to heparin in the antiphospholipid syndrome. Lupus. 10:2001;778
23. Liou H.H., Wang C.R., Chen C.J., et al. Elevated levels of anticardiolipin antibodies and epilepsy in lupus patients. Lupus. 5:1996;307-312
24. Verrot D., San-Marco M., Dravet C., et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am. J. Med. 103:1997;33-37
25. Herranz M.T., Rivier G., Khamashta M.A., Blaser K.U., Hughes G.R.V. Association between antiphospholipid antibodies and epilepsy in patients with systemic lupus erythematosus. Arthritis Rheum. 1994;568-571
26. Peltola J.T., Haapala A., Isojarvi J.I., et al. Antiphospholipid and antinuclear antibodies in patients with epilepsy or new-onset seizure disorders. Am. J. Med. 109:2000;712-717
27. Sanna G., Bertolaccini M.L., Cuadrado M.J., et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J. Rheumatol. 30:2003;985-992
28. Asherson R.A., Hughes G.R.V. Antiphospholipid antibodies and chorea. J. Rheumatol. 15:1988;377-379
29. Cervera R., Asherson R.A., Font J., et al. Chorea in the antiphospholipid syndrome. Clinical, radiologic and immunologic characteristics of 50 patients from our clinics and the recent literature. Medicine (Baltimore). 76:1997;203-212
30. Nordal E.B., Nielsen J., Marhaug G. Chorea in juvenile primary antiphospholipid syndrome. Reversible decreased circulation in the basal ganglia visualized by single photon emission computed tomography. Scand. J. Rheumatol. 28:1999;324-327
31. Fernando S.J. An attack of chorea complicating oral contraceptive therapy. Practitioner. 197:1996;210-211
32. Molad Y., Sidi Y., Gornish M., Lerner M., Pinkhas J., Weinberger A. Lupus anticoagulant: correlation with magnetic resonance imaging of brain lesions. J. Rheumatol. 19:1992;556-561
33. Cuadrado M.J., Khamashta M.A., Ballesteros A., Godfrey T., Simon M.J., Hughes G.R.V. Can Hughes' (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 79:2000;57-68
34. Karussis D., Leker R.R., Ashkenazi A., Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity? Ann. Neurol. 44:1998;629-634
35. Hanly J.G., Hong C., Smith S., Fisk J.D. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum. 42:1999;728-734
36. Menon S., Jameson-Shortall E., Newman S.P., Hall-Craggs M.R., Chinn R., Isenberg D.A. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 42:1999;735-741
37. Schwartz M., Rochas M., Weller B., et al. High association of anticardiolipin antibodies with psychosis. J. Clin. Psychiatry. 59:1998;20-23
38. Kovacs B., Lafferty T.L., Brent L.H., DeHoratius R.J. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann. Rheum. Dis. 59:2000;120-124
39. Blank M., Krause I., Shoenfeld Y. The contribution of experimental models to our understanding of etiology, pathogenesis and novel therapies in the antiphospholipid syndrome. Khamashta M.A. Hughes syndrome: antiphospholipid syndrome. 2000;379-390 Springer, London
40. Wiechens B., Schroder J.O., Potzsch B., Rochels R. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am. J. Ophthalmol. 123:1997;848-850
41. Giorgi D., Gabrieli C.B., Bonomo L. The clinical opthalmological spectrum of antiphospholipid syndrome. Ocul. Immunol. Inflamm. 6:1998;269-273
42. Cordeiro M.F., Lloyd M.E., Spalton D.J., Hughes G.R.V. Ischaemic optic neuropathy, transverse myelitis and epilepsy in an antiphospholipid positive patient with systemic lupus erythematosus. J. Neurol. Neurosurg. Psychiatry. 57:1994;1142-1143
43. Casoli P., Tumiati B. Cogan's syndrome: a new possible complication of antiphospholipid antibodies? Clin. Rheumatol. 14:1995;197-198
44. Naarendorp M., Spiera H. Sudden sensorineural hearing loss in patients with systemic lupus erythematosus or lupus-like syndromes and antiphospholipid antibodies. J. Rheumatol. 25:1998;589-592
45. Leker R.R., Steiner I. Anticardiolipin antibodies are frequently present in patients with idiopathic intracranial hypertension. Arch. Neurol. 55:1998;817-820
46. Milanov I., Bogdanova D. Antiphospholipid syndrome and dystonia-parkinsonism. A case report. Parkinsonism Relat. Disord. 7:2001;139-141
47. Shah M.N., Khamashta M.A., Atsumi T., Hughes G.R.V. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus. 7:1998;3-6
48. Khamashta M.A., Cuadrado M.J., Mujic F., et al. The management of thrombosis in the antiphospholipid antibody syndrome. New Engl. J. Med. 332:1995;993-997
49. Ruiz-Irastorza G., Khamashta M.A., Hunt B.J., Escudero A., Cuadrado M.J., Hughes G.R.V. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch. Intern. Med. 162:2002;1164-1169